The Bottom Line

Harry Destecroix was studying for his PhD at Bristol University when he co-founded Ziylo. Based on 20 years of Bristol chemistry research, the spin-out company created a new technology that can be developed to treat diabetes more effectively. It's a breakthrough that led to its acquisition by pharmaceutical firm, Novo Nordisk, in a deal reportedly worth up to 600 million pounds. Harry has also founded the incubator, Science Creates and is the founding managing partner of SCVC, a venture capital firm. Harry tells Evan Davis why his own experience of spinning out a company has made him passionate to help other early-stage companies in the Bristol area – whether that’s providing lab space, finance or advice.(Image: Harry Destecroix Credit: Peter Schiazza, Copyright: Science Creates)